Alvotech (ALVO) Form 6-K — Jun 8, 2026
Alvotech announced that the FDA has accepted its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), for review. This regulatory acceptance marks a critical milestone for the company’s immunology pipeline, with a review period expected to last up to six months. Under a partnership with Teva, Alvotech handles development and manufacturing while Teva manages US commercialization. The filing also includes unaudited Q1 2026 financial results, reporting total revenues of $105.9 million, a 20% decline from $132.8 million in Q1 2025, attributed to a temporary production slowdown during facility improvements.
Key figures
- Eps
- 0
- Revenue
- 105865000
- Guidance
- Total revenues $650-$700 million; Adjusted EBITDA $180-$220 million for 2026
- Net Income
- 1030000
- Total Debt
- 1309631000
- Cash Position
- 63832000
- Gross Margin
- 57%
- Adjusted Ebitda
- 24400000
- Shares Outstanding
- 312153164
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.